The intraoperative margin assessment device market is projected to grow from USD 691.3 million in 2026 to USD 1,713.2 million by 2036, at a CAGR of 9.5%. Optical spectroscopy systems will dominate with a 42.0% market share, while breast cancer will lead the application segment with a 56.0% share.